Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
1.93 EUR | 0.00% | +7.22% | +77.06% |
May. 16 | GeNeuro SA Announces Last Patient Last Visit in Its Post-Covid Trial and Confirms Top-Line Results by End of June 2024 | CI |
Mar. 20 | Geneuro SA Announces Appointments of Board of Directors | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+77.06% | 62.03M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+43.00% | 40.47B | |
-10.02% | 27.17B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- GNRO Stock
- News GeNeuro SA
- GeNeuro Lands EUR25 Million Loan to Advance Long COVID-19 Trial